Scarica l'app Stockscreener
12.02
0.42%
0.05
Pre-mercato:
12.00
-0.02
-0.17%
Kura Oncology Inc Borsa (KURA) Ultime notizie
Kura Oncology stock rating reiterated at Market Outperform by Citizens - Investing.com Canada
FDA approved five NMEs in November - biocentury.com
Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points - The Malaysian Reserve
Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points - Benzinga
Kura Oncology (NASDAQ:KURA) Trading Up 7.3%What's Next? - MarketBeat
Kura Oncology: A Cautious Buy (NASDAQ:KURA) - Seeking Alpha
Kura Oncology to Host Virtual Investor Event to Discuss Data Presented at ASH 2025 on Triplet Combination of Ziftomenib (KOMZIFTI®) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia - The Manila Times
Kura Oncology to Host Virtual Investor Event to Discuss - GlobeNewswire
Geode Capital Management LLC Purchases 211,470 Shares of Kura Oncology, Inc. $KURA - MarketBeat
Kura Oncology (KURA) Is Down 7.2% After First KOMZIFTI Sale Triggers $135M Milestone Payment - simplywall.st
Kura Oncology: Expect Volatility Following Ziftomenib Phase 1b Data (NASDAQ:KURA) - Seeking Alpha
Kura Oncology, Inc. Completes Collaboration and License Agreement with Kyowa Kirin - marketscreener.com
Kura Oncology Expects $135 Million Milestone Payment for First US Sale of Komzifti - marketscreener.com
Kura Oncology (KURA) Secures $135 Million Milestone with KOMZIFT - GuruFocus
Kura Oncology completes first commercial sale of leukemia drug - Investing.com
Kura Oncology completes first U.S. commercial sale of KOMZIFTI - TipRanks
Kura Oncology announces first US sale of KOMZIFTI, triggering $135 million payment - Investing.com
Kura Oncology Announces First U.S. Sale of KOMZIFTI - TipRanks
Kura Oncology completes first commercial sale of leukemia drug By Investing.com - Investing.com India
First U.S. commercial sale of Komzift triggers $135 million milestone payment to Kura Oncology - MarketScreener
First U.S. Commercial Sale of KOMZIFTI™ Triggers $135 Million Milestone Payment to Kura Oncology Under Collaboration and License Agreement with Kyowa Kirin - The Manila Times
Kura Oncology (Nasdaq: KURA) to receive $135M as KOMZIFTI launches in U.S. market - Stock Titan
First U.S. Commercial Sale of KOMZIFTI™ Triggers $135 - GlobeNewswire
How Kura Oncology Inc. stock trades during market volatilityRate Hike & Daily Growth Stock Investment Tips - Newser
How geopolitical tensions affect Kura Oncology Inc. stockWeekly Stock Report & Technical Confirmation Trade Alerts - Newser
How rising interest rates impact Kura Oncology Inc. stock - Newser
What drives Kura Oncology Inc stock priceSector Performance Drivers & Swing Trade Smarter With Data Insights - earlytimes.in
Magnetar Financial LLC Buys 64,345 Shares of Kura Oncology, Inc. $KURA - MarketBeat
KOMZIFTI™ (ziftomenib) Added to National Comprehensive Cancer Network® (NCCN) Guidelines for Acute Myeloid Leukemia (AML) - The Manila Times
Kura Oncology’s leukemia drug added to NCCN treatment guidelines By Investing.com - Investing.com Australia
Kura Oncology’s leukemia drug added to NCCN treatment guidelines - Investing.com UK
Kura Oncology stock rises after KOMZIFTI added to NCCN treatment guidelines - Investing.com Canada
Kura Oncology and Kyowa Kirin's KOMZIFTI™ Approved and Included in NCCN Guidelines for Treatment of Relapsed/Refractory AML with NPM1 Mutation - Quiver Quantitative
KOMZIFTI™ (ziftomenib) Added to National Comprehensive - GlobeNewswire
Kura Oncology (NASDAQ: KURA) KOMZIFTI Named NCCN Category 2A Option for R/R NPM1 AML - Stock Titan
Kura Oncology (KURA) Is Up 8.1% After FDA Approval of KOMZIFTI for NPM1-Mutated AML – What's Changed - Yahoo Finance
Barclays Remains a Buy on Kura Oncology (KURA) - The Globe and Mail
Barclays Raises Price Target for Kura Oncology (KURA) to $28 | K - GuruFocus
Barclays Maintains Kura Oncology (KURA) Overweight Recommendation - MSN
KURA Stock Rises Pre-Market After Receiving Milestone Payment Related To Cancer Drug Development Agreement - MSN
Is Kura Oncology Inc a good long term investmentMarket Entry Points & Free Exceptional Risk Adjusted Gains - earlytimes.in
Why The Narrative Around Kura Oncology Is Shifting After FDA Approval and Analyst Upgrades - Yahoo Finance
(KURA) Price Dynamics and Execution-Aware Positioning - news.stocktradersdaily.com
Will Kura Oncology Inc. stock benefit from infrastructure spendingQuarterly Growth Report & Stock Timing and Entry Methods - newser.com
How Kura Oncology Inc. stock performs in high volatility marketsEarnings Growth Summary & Long-Term Safe Investment Plans - newser.com
Kura Oncology at Jefferies Conference: Strategic Insights on Zypto By Investing.com - Investing.com Canada
Can Kura Oncology Inc. stock resist market sell offs2025 Macro Impact & Consistent Income Trade Ideas - newser.com
Is Kura Oncology Inc. showing signs of accumulationQuarterly Market Summary & High Return Stock Watch Alerts - newser.com
Is Kura Oncology Inc. stock recession proofJuly 2025 Summary & Free Long-Term Investment Growth Plans - newser.com
How to monitor Kura Oncology Inc. with trend dashboards2025 Risk Factors & AI Powered Market Entry Strategies - newser.com
Candlestick signals on Kura Oncology Inc. stock todayJuly 2025 Sentiment & Detailed Earnings Play Strategies - newser.com
Can Kura Oncology Inc. stock resist sector downturnsRecession Risk & Daily Growth Stock Investment Tips - newser.com
1.10%
1.10%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):